Apyx Medical Corporation (APYX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Apyx Medical Corporation (APYX) Healthcare & Pipeline Overview

Apyx Medical Corporation develops and markets energy-based medical devices, primarily Renuvion, for cosmetic and surgical applications. The company's focus on helium plasma technology differentiates it within the medical device sector, targeting plastic surgery and hospital surgical markets globally with a direct sales and OEM model.

What Is the Investment Thesis for APYX?

Apyx Medical Corporation presents a compelling investment case based on its innovative Renuvion technology and expanding applications in the cosmetic and surgical markets. The company's focus on energy-based solutions offers a differentiated approach to tissue coagulation and ablation, potentially driving adoption among surgeons and physicians. Key value drivers include increasing Renuvion utilization in existing markets, expanding into new geographic regions, and securing regulatory approvals for additional applications. The company's gross margin of 38.1% indicates potential for profitability as revenue scales. However, investors should be aware of the company's negative profit margin of -16.4% and the competitive landscape within the medical device industry. Upcoming catalysts include potential regulatory approvals and expansion into new markets. The company's beta of 1.66 suggests higher volatility compared to the broader market.

Based on FMP financials and quantitative analysis

APYX Key Highlights

Apyx Medical Corporation operates in the Advanced Energy and Original Equipment Manufacturing (OEM) segments.

• The company's Renuvion product is used in the cosmetic surgery market for tissue coagulation and ablation.
• Apyx Medical's J-Plasma product is used in the hospital surgical market.
• The company has a gross margin of 38.1%.
• Apyx Medical Corporation has a market capitalization of $131M.

Who Are APYX's Competitors?

APYX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are APYX's Key Strengths?

Innovative Renuvion technology

• Established presence in the cosmetic surgery market
• Strong relationships with surgeons and physicians
• Proprietary technology protected by patents

What Are APYX's Weaknesses?

Negative profit margin

• Reliance on a limited number of products
• Limited financial resources compared to larger competitors
• High beta indicating higher volatility

What Could Drive APYX Stock Higher?

Potential regulatory approvals for new Renuvion applications in specific surgical procedures.

• Expansion into new geographic markets, particularly in Europe and Asia.
• Increasing utilization of Renuvion technology among existing customers through training and support programs.
• Potential strategic partnerships with established medical device companies or distributors.

What Are the Key Risks for APYX?

Financial-distress signal — its Altman Z-Score of 1.11 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-90.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Intense competition from larger medical device companies with greater financial resources.
• Evolving regulatory standards that could impact the approval and commercialization of Apyx Medical's products.
• Product liability claims related to the use of Apyx Medical's devices.
• Economic downturn affecting demand for cosmetic procedures.

What Are the Growth Opportunities for APYX?

• Expanding Renuvion Applications: Apyx Medical has the opportunity to expand the applications of its Renuvion technology beyond current cosmetic procedures. Exploring new surgical applications, such as general surgery or orthopedic procedures, could significantly increase the addressable market. Timeline: Ongoing, with continuous research and development efforts.
• Geographic Expansion: Apyx Medical can pursue growth by expanding its geographic presence, particularly in international markets. Entering new markets in Europe, Asia, and Latin America could drive revenue growth and diversify the company's customer base. This expansion requires navigating regulatory hurdles and establishing distribution networks, but the potential market size is significant. Timeline: Near-term, with ongoing efforts to secure regulatory approvals and establish partnerships in key international markets.
• Strategic Partnerships and OEM Agreements: Apyx Medical can leverage strategic partnerships and OEM agreements to expand its reach and market penetration. Collaborating with established medical device companies or distributors can provide access to new markets and customer segments. These partnerships can also reduce the company's reliance on direct sales and marketing efforts. Timeline: Ongoing, with continuous efforts to identify and pursue strategic partnerships.
• New Product Development: Apyx Medical can invest in new product development to expand its portfolio and address unmet needs in the cosmetic and surgical markets. Developing next-generation energy-based devices or complementary products could enhance the company's competitive position and drive revenue growth. This requires significant investment in research and development, but the potential return is substantial. Timeline: Mid-term, with ongoing research and development efforts focused on next-generation technologies.
• Increased Utilization of Existing Products: Apyx Medical can focus on increasing the utilization of its existing Renuvion and J-Plasma products among current customers. Providing training and support to surgeons and physicians can encourage greater adoption of the technology. This can be achieved through workshops, webinars, and on-site training programs. Increased utilization can lead to higher revenue and improved customer satisfaction. Timeline: Ongoing, with continuous efforts to provide training and support to customers.

What Are APYX's Competitive Advantages?

• Proprietary Helium Plasma Technology: Apyx Medical's Renuvion technology is protected by patents and trade secrets, providing a competitive advantage.
• Established Brand Recognition: The Renuvion brand has gained recognition in the cosmetic surgery market, creating a barrier to entry for competitors.
• Strong Relationships with Surgeons and Physicians: Apyx Medical has cultivated strong relationships with key opinion leaders in the cosmetic and surgical fields.
• Regulatory Approvals: Securing regulatory approvals for its products creates a barrier to entry for competitors.

What Does APYX Do?

Apyx Medical Corporation, formerly Bovie Medical Corporation, was founded in 1982 and is headquartered in Clearwater, Florida. The company operates as an energy technology entity, specializing in the design, manufacture, and sale of medical devices across the cosmetic and surgical sectors. Apyx's core technology revolves around its Helium Plasma Generator, which delivers radiofrequency (RF) energy and helium to cut, coagulate, and ablate soft tissue during both open and laparoscopic surgical procedures. The company's product portfolio is divided into two main segments: Advanced Energy and Original Equipment Manufacturing (OEM). The Advanced Energy segment features the Renuvion branded products, tailored for the cosmetic surgery market. These products enable plastic surgeons, facial plastic surgeons, and cosmetic physicians to precisely control heat application to tissue, achieving desired aesthetic outcomes. The J-Plasma branded products cater to the hospital surgical market. In addition to generators, Apyx Medical also develops, manufactures, and sells disposable hand pieces, OEM generators, and accessories. The company serves a global market, reaching customers through a direct sales force and strategic OEM partnerships.

What Products and Services Does APYX Offer?

• Develops Helium Plasma Generator for surgical procedures.
• Offers Renuvion branded products for cosmetic surgery.
• Provides J-Plasma branded products for hospital surgical market.
• Manufactures and sells disposable hand pieces.
• Offers OEM generators and accessories.
• Provides energy-based solutions for cutting, coagulating, and ablating soft tissue.

How Does APYX Make Money?

• Develops and manufactures medical devices using helium plasma technology.
• Sells products directly to plastic surgeons, cosmetic physicians, and hospitals.
• Generates revenue through the sale of generators, hand pieces, and accessories.
• Partners with OEM companies to integrate its technology into their products.

What Industry Does APYX Operate In?

Apyx Medical Corporation operates within the medical device industry, a sector characterized by technological innovation, stringent regulatory requirements, and intense competition. The market for energy-based surgical devices is growing, driven by increasing demand for minimally invasive procedures and aesthetic treatments. Apyx competes with larger, established medical device companies. The industry is subject to evolving regulatory standards, particularly from the FDA and similar international bodies. Apyx's success depends on its ability to innovate, secure regulatory approvals, and effectively market its products to surgeons and physicians.

Who Are APYX's Key Customers?

• Plastic surgeons
• Facial plastic surgeons
• Cosmetic physicians
• Hospitals

Wall Street analysts project Apyx Medical Corporation revenue of about $59.6M for fiscal 2026, with EPS near $-0.27. The estimate reflects 3 contributing analysts.

Apyx Medical Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.11 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Apyx Medical Corporation stands at -90.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -14.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.4%, the inverse of the P/E and a quick read on earnings relative to price.

Apyx Medical Corporation (APYX) Valuation Context

Valued at $131M, APYX is classified as a micro-cap stock. Relative to its peer group, APYX's quantitative score of 33/100 is below the peer average of 63/100.

APYX Revenue & Earnings Trend

In Q2 2026, APYX generated $13.9M in top-line revenue, marking a sequential increase of 11.2%. The company recorded a net loss of $3.2M, with diluted EPS of $-0.08. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, APYX averaged $-0.05 in diluted EPS.

Company Profile

Apyx Medical Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Clearwater, US. The company is led by CEO Charles D. Goodwin. APYX has traded publicly since 2019.

APYX Financials

APYX Latest News

APYX Analyst Consensus

APYX MoonshotScore

APYX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources